Clinical Trial Update: Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ABEMACICLIB monotherapy in patients with locally advanced or metastatic head and neck cancer after platinum and cetuximab/anti-EGFR the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)

Snippet

Sponsor: Centre Leon Berard | Conditions: Head and Neck Cancer, Advanced Cancer | Phase 2 | Status: COMPLETED